21,000 Shares in Tempus AI, Inc. $TEM Purchased by Hussman Strategic Advisors Inc.

Key Points

• Hussman Strategic Advisors established a new position in Tempus AI by purchasing 21,000 shares (~$1.695M) in Q3, and several other institutions also added or increased stakes, leaving institutional investors with 24.22% ownership.
• Insiders have been active sellers recently—CEO Eric P. Lefkofsky sold 166,250 shares (~$10.64M) and insiders sold 600,332 shares in the last 90 days, though corporate insiders still own 26.27% of the company.
• Tempus beat Q3 EPS estimates (reported -$0.11 vs. -$0.16) with revenue of $334.2M (+84.7% YoY); the stock trades near $64.57 (52-week range $36.22–$104.32) and carries a consensus Hold rating with an average price target of $87.20.

Hussman Strategic Advisors Inc. bought a new position in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 21,000 shares of the company's stock, valued at approximately $1,695,000.

Several other large investors have also modified their holdings of TEM. Belpointe Asset Management LLC purchased a new stake in shares of Tempus AI in the 3rd quarter worth approximately $566,000. NWF Advisory Services Inc. purchased a new stake in Tempus AI during the third quarter worth $906,000. Fortis Capital Advisors LLC purchased a new stake in Tempus AI during the third quarter worth $566,000. Pier 88 Investment Partners LLC boosted its position in Tempus AI by 94.2% during the 3rd quarter. Pier 88 Investment Partners LLC now owns 8,740 shares of the company's stock valued at $705,000 after acquiring an additional 4,240 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC increased its holdings in shares of Tempus AI by 14.0% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 5,511 shares of the company's stock valued at $445,000 after acquiring an additional 676 shares during the period. Institutional investors own 24.22% of the company's stock.

Insider Activity

In related news, Director Jennifer A. Doudna sold 676 shares of the company's stock in a transaction on Monday, December 1st. The stock was sold at an average price of $75.55, for a total value of $51,071.80. Following the transaction, the director directly owned 23,952 shares of the company's stock, valued at $1,809,573.60. This represents a 2.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Eric P. Lefkofsky sold 166,250 shares of the firm's stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $63.99, for a total value of $10,638,337.50. Following the completion of the transaction, the chief executive officer owned 8,974,783 shares of the company's stock, valued at $574,296,364.17. This trade represents a 1.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 600,332 shares of company stock valued at $41,554,949. 26.27% of the stock is owned by corporate insiders.

Tempus AI Price Performance

Shares of TEM stock opened at $64.57 on Thursday. Tempus AI, Inc. has a fifty-two week low of $36.22 and a fifty-two week high of $104.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 3.12 and a current ratio of 3.28. The firm has a market capitalization of $11.49 billion, a price-to-earnings ratio of -54.26 and a beta of 5.22. The stock's 50-day simple moving average is $68.81 and its 200-day simple moving average is $73.95.

Tempus AI (NASDAQ:TEM - Get Free Report) last released its earnings results on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.05. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The company had revenue of $334.21 million during the quarter, compared to analysts' expectations of $328.89 million. During the same period last year, the business earned ($0.46) EPS. Tempus AI's revenue for the quarter was up 84.7% on a year-over-year basis. As a group, equities analysts forecast that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on TEM shares. Weiss Ratings restated a "sell (d-)" rating on shares of Tempus AI in a research note on Thursday, January 22nd. JPMorgan Chase & Co. reduced their target price on shares of Tempus AI from $85.00 to $80.00 and set a "neutral" rating for the company in a report on Monday, December 15th. Morgan Stanley raised their price target on shares of Tempus AI from $80.00 to $85.00 and gave the company an "overweight" rating in a report on Monday, December 1st. Needham & Company LLC lifted their price objective on shares of Tempus AI from $70.00 to $100.00 and gave the stock a "buy" rating in a research report on Wednesday, November 5th. Finally, BTIG Research increased their target price on shares of Tempus AI from $96.00 to $105.00 and gave the company a "buy" rating in a research report on Tuesday, November 25th. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Tempus AI presently has a consensus rating of "Hold" and an average price target of $87.20.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.